Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis

Therapeutics and Clinical Risk Management

Volumn 6, Issue 1, 2010, Pages 123-141

  Koutruba, Nora ^a   Emer, Jason ^a   Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biologics; Interleukin 12; Interleukin 23; Plaque psoriasis; Ustekinumab

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETA INTERFERON; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLATIRAMER; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; REMICAIDE; SALAZOSULFAPYRIDINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB;

ARTHRALGIA; ATYPICAL MYCOBACTERIOSIS; BASAL CELL CARCINOMA; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELLULITIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DIVERTICULITIS; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FLANK PAIN; GASTRIC ULCER BLEEDING; GASTROENTERITIS; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOMYELITIS; PNEUMONIA; PROSTATE CANCER; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; ROTATOR CUFF INJURY; SALMONELLA ENTERITIDIS; SALMONELLOSIS; SKIN CANCER; STOMACH ULCER; STROKE; SYNCOPE; TH1 CELL; TH17 CELL; THORAX PAIN; TONSIL CANCER; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 77950848197     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther. 2009;22(1):56-60.
2. Bilac C, Ermertcan AT, Bilac DB, Deveci A, Horasan GD. The relationship between symptoms and patient characteristics among psoriasis patients. Indian J Dermatol Venereol Leprol. 2009;75(5):551.
3. Van Voorhees AS, Fried R. Depression and quality of life in psoriasis. Postgrad Med. 2009;121(4):154-161.
4. National Psoriasis Foundation. http://www.psoriasis.org/netcommunity/ learn_statistics. Accessed Dec 19, 2009.
5. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87-113.
6. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol. 2002;2(12):933-944.
7. Chien AL, Elder JT, Ellis CN. Ustekinumab: a new option in psoriasis therapy. Drugs. 2009;69(9):1141-1152.
8. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-725.
9. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007;19(3):281-286.
10. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005 Nov; 6(11): 1123-1132.
11. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: ran-domised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633-640.
12. Cuchacovich RS, Espinoza LR. Ustekinumab for psoriatic arthritis. Lancet. 2009;373(9664):605-606.
13. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: a new therapeutic target in inflammatory dermatoses. J Dermatolog Treat. 2008;19(6):318-326.
14. Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008;14(3):282-289.
15. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648-651.
16. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epider-mal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12): 2577-2587.
17. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleu-kin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092-1102.
18. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36(5):1309-1323.
19. Siegemund S, Schütze N, Schulz S, et al. Differential IL-23 require-ment for IL-22 and IL-17A production during innate immunity against Salmonella enterica serovar Enteritidis. Int Immunol. 2009;21(5): 555-565.
20. Schulz SM, Köhler G, Schütze N, et al. Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol. 2008;181(11):7891-7901.
21. Godinez I, Raffatellu M, Chu H, et al. Interleukin-23 orchestrates mucosal responses to Salmonella enterica serotype Typhimurium in the intestine. Infect Immun. 2009;77(1):387-398.
22. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119(12):3573-3585.
23. Tohyama M, Hanakawa Y, Shirakata Y, et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol. 2009;39(10): 2779-2788.
24. Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006 1;177(7):4917-4926.
25. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;175(4):2721-2729.
26. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epider-mal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183-3194.
27. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic associa-tion study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273-290.
28. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122(2):201-206.
29. Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128(7):1653-1661.
30. Chen X, Tan Z, Yue Q, Liu H, Liu Z, Li J. The expression of interleukin-23 (p19/p40) and inteleukin-12 (p35/p40) in psoriasis skin. J Huazhong Univ Sci Technolog Med Sci. 2006;26(6):750-752.
31. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176(3):1908-1915.
32. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125-130.
33. Tsunemi Y, Saeki H, Nakamura K, et al. Interleukin-12 p40 gene (IL12B) 3'-untranslated region polymorphism is associated with sus-ceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci. 2002;30(2):161-166.
34. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41(2):199-204.
35. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950-957.
36. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123(6):1037-1044.
37. Sobell JM, Kalb RE, Weinberg JM. Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents. J Drugs Dermatol. 2009;8(3):230-238.
38. Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administra-tions of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007;23(5):1081-1092.
39. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580-592.
40. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-1674.
41. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675-1684.
42. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009;22(5):431-440.
43. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162-175.
44. Griffiths CEM, Strober B, Fidelus-Gort R, Menter A. A Phase 3, Multicenter, Randomized Study Comparing Ustekinumab and Etaner-cept for the Treatment of Moderate to Severe Plaque Psoriasis. P3318. 2009 AAD meeting, San Francisco.
45. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009;58(8):1152-1167.
46. Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut. 2008;57(12):1682-1689.
47. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135(4):1130-1141.
48. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7(9):796-804.
49. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421(6924):744-748.
50. Touil T, Fitzgerald D, Zhang GX, Rostami AM, Gran B. Pathophysiol-ogy of interleukin-23 in experimental autoimmune encephalomyelitis. Drug News Perspect. 2006;19(2):77-83.
51. Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med. 1998;187(4):537-546.
52. Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother. 2009;9(3):319-321
53. Ma CS, Chew GY, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205(7):1551-1557.
54. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452(7188):773-776.
55. Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med. 1999;340(9):692-702.
56. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmo-nella infections in interleukin-12 receptor-deficient patients. Science. 1998;280(5368):1435-1438.
57. Altare F, Durandy A, Lammas D, et al. Impairment of mycobacte-rial immunity in human interleukin-12 receptor deficiency. Science. 1998;280(5368):1432-1435.
58. Altare F, Lammas D, Revy P, et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis dis-seminated infection. J Clin Invest. 1998;102(12):2035-2040.
59. Fieschi C, Casanova JL. The role of interleukin-12 in human infectious dis-eases: only a faint signature. Eur J Immunol. 2003;33(6):1461-1464.
60. Esther van de Vosse, Ottenhoff TH. Human host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity. Microbes Infect. 2006;8(4):1167-1173.
61. MacLennan C, Fieschi C, Lammas DA, et al. Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J Infect Dis. 2004;190(10):1755-1757.
62. Filipe-Santos O, Bustamante J, Chapgier A, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol. 2006;18(6):347-361.
63. Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008;58(1):94-105.
64. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59(2):209-217.
65. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther. 2007;7(11):1705-1721.
66. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2009 Nov 9. [Epub ahead of print]
67. Zhou H, Hu C, Zhu Y, et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009 Nov 23 [Epub ahead of print].
68. Stelara™ (ustekinumab) [package insert]. http://www.stelarainfo. com/stelarainfo/assets/pdf/PrescribingInformation.pdf. Accessed Oct 1, 2009.
69. Maeda A, Schneider SW, Kojima M, Beissert S, Schwarz T, Schwarz A. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res. 2006;66(6):2962-2969.
70. Meeran SM, Mantena SK, Meleth S, Elmets CA, Katiyar SK. Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. Mol Cancer Ther. 2006;5(4):825-832.
71. Enbrel® (etanercept) [package insert]. http://www.enbrel.com/pdf/ enbrel_pi.pdf. Accessed Oct 12, 2009.
72. Humira® (adalimumab) [package insert]. http://www.rxabbott.com/pdf/ humira.pdf. Accessed Oct 1, 2009.
73. Remicade® (infliximab) [package insert]. http://www.remicade.com/ remicade/assets/HCP_PPI.pdf. Accessed Oct 12, 2009.
74. Amevive® (alefacept) [package insert] http://www.astellas.us/docs/ amevive.pdf. Accessed Oct 12, 2009.